DDC Enterprise Acquires Additional 50 BTC, Reinforcing Steady and Disciplined Treasury Strategy

DDC Enterprise Limited ("DDC" or the "Company"), a leading innovator in corporate Bitcoin treasury strategy and a global Asian food platform, today announced the acquisition of an additional 50 BTC , bringing its total holdings to 1,058 BTC .

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250925180166/en/

This latest purchase continues DDC's consistent approach to Bitcoin accumulation, even as broader market sentiment remains cautious. The Company remains committed to its strategy of responsibly building one of the largest corporate Bitcoin treasuries globally.

Purchase Highlights:

  • Treasury Growth: Increases treasury holdings by 50 BTC. DDC's average cost per bitcoin holding is USD 108,665.
  • BTC Milestone: Reaches 1,058 BTC.
  • Improved Yield: 1556% Yield increase compared to its first purchase in May 2025.
  • Shareholder Value: The updated holdings translate to 0.105808 BTC per 1,000 DDC shares.

"We believe in a disciplined, long-term strategy—not a one-time bet," said Norma Chu , Founder, Chairwoman, and CEO of DDC. "Every purchase demonstrates our conviction that Bitcoin is the strongest foundation for preserving and growing shareholder value over decades. We remain focused on our goal: 10,000 BTC by the end of this year."

About DDC Enterprise Limited

DDC Enterprise Limited (NYSE: DDC) is spearheading the corporate Bitcoin treasury revolution while maintaining its foundation as a leading global Asian food platform. The Company has strategically positioned Bitcoin as a core reserve asset, executing a bold and accelerating accumulation strategy. While continuing to grow its portfolio of culinary brands, DDC is at the vanguard of public companies integrating Bitcoin into their financial architecture. For more information, visit www.ddc.xyz .

Caution Regarding Forward-Looking Statements

Certain statements in this announcement are forward-looking statements.

Investors can identify these forward-looking statements by words or phrases such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "is/are likely to," "potential," "continue" or other similar expressions. Examples of forward-looking statements include those related to business prospects, accumulation of Bitcoin, and the Company's goals and future activity under the financing transactions described above, including the statements on the closings of the offerings and the satisfaction of closing conditions and use of proceeds in the offerings. These statements are subject to uncertainties and risks including, but not limited to, the risk factors discussed in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our Forms 20-F, 6-K and other reports, including a Form 6-K which with copies of the definitive documents related to the above transactions, to be filed with the Securities and Exchange Commission ("SEC") and available at www.sec.gov . It is also inherent in forward-looking statements for there to be risks, uncertainties and other factors beyond the Company's ability to predict or control. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's filings with the SEC. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov . The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations that arise after the date hereof, except as may be required by law.

Media & Investor Contacts:

DDC Investor Relations

Orange Group | Yujia Zhai
ddc@orangegroupadvisors.com

DDC Press and Media
pr@ddc.xyz

News Provided by Business Wire via QuoteMedia

DDC
The Conversation (0)
Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-1511 for the Treatment of Advanced Solid Tumors

Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-1511 for the Treatment of Advanced Solid Tumors

NUV-1511 is the first clinical candidate from the company's novel drug-drug conjugate platform Company anticipates initiating a Phase 1/2 clinical study of NUV-1511 in 1H 2024 Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by... Keep Reading...
Nuvation Bio Reports Third Quarter 2023 Financial Results and Provides Business Update

Nuvation Bio Reports Third Quarter 2023 Financial Results and Provides Business Update

Phase 1 monotherapy study of NUV-868 and Phase 1b study of NUV-868 in combination with olaparib or enzalutamide are ongoing Expect to submit an IND for first Drug-Drug Conjugate (DDC) clinical candidate by year end 2023 Strong balance sheet with cash, cash equivalents, and marketable securities... Keep Reading...
Nuvation Bio Reports Second Quarter 2023 Financial Results and Provides Business Update

Nuvation Bio Reports Second Quarter 2023 Financial Results and Provides Business Update

Enrollment ongoing in the Phase 1b study of NUV-868 in combination with olaparib or enzalutamide Enrollment ongoing in the Phase 1 monotherapy study of NUV-868 Expect to submit an IND for first Drug-Drug Conjugate (DDC) clinical candidate by year end 2023 Announced formation of oncology-focused... Keep Reading...
Nuvation Bio Announces Formation of Oncology-Focused Scientific Advisory Board

Nuvation Bio Announces Formation of Oncology-Focused Scientific Advisory Board

Scientific Advisory Board members bring significant global expertise in oncology drug and clinical development Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today... Keep Reading...
Nuvation Bio Reports First Quarter 2023 Financial Results and Provides Business Update

Nuvation Bio Reports First Quarter 2023 Financial Results and Provides Business Update

Enrollment ongoing in the Phase 1b study of NUV-868 in combination with olaparib or enzalutamide Enrollment ongoing in the Phase 1 monotherapy study of NUV-868 Expect to submit an IND for first Drug-Drug Conjugate (DDC) clinical candidate by year end 2023 Strong balance sheet with cash, cash... Keep Reading...

Charles Schwab's Money Talk Personal Finance Column Expands Bench of Expert Voices

Three new Certified Financial Planners ® join the column's roster of experts creating real-life financial education insight Charles Schwab today announced the addition of three new Certified Financial Planners® to Money Talk, Schwab's personal finance column designed to help everyday Americans... Keep Reading...

Climate Global and Moody's Power the First Index and ETF of Climate-Resilient REITs

Climate Global and Exchange Traded Concepts announced the Climate Global Climate-Resilient REIT Index ETF (Ticker: CLIM), an exchange-traded fund designed to provide exposure to U.S. equity Real Estate Investment Trusts (REITs) while systematically incorporating insurance-grade climate and... Keep Reading...

T. ROWE PRICE OHA SELECT PRIVATE CREDIT FUND ANNOUNCES DECEMBER 31, 2025 FINANCIAL RESULTS AND DECLARED TOTAL DISTRIBUTIONS OF $0.69 PER SHARE IN Q4 2025

T. Rowe Price OHA Select Private Credit Fund (the "Company" or "OCREDIT") today reported financial results and total distributions of $0.69 per share for the quarter ended December 31, 2025. As private credit remains a key driver of financing solutions within credit markets, OCREDIT closed the... Keep Reading...
AmeriTrust Provides Corporate Update

AmeriTrust Provides Corporate Update

TORONTO, ON / ACCESS Newswire / March 11, 2026 / AmeriTrust Financial Technologies Inc. (TSXV:AMT,OTC:AMTFF)(OTCQB:AMTFF)(Frankfurt:1ZVA) ("AmeriTrust", "AMT" or the "Company"), a fintech platform targeting automotive finance is pleased to provide an update of corporate activities since the... Keep Reading...

Interactive Chart

Latest Press Releases

Related News